TLDR: Indegene has been named a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025 by Everest Group. This recognition highlights Indegene’s comprehensive AI and analytics solutions, particularly its focus on embedding Generative AI and Agentic AI capabilities across its commercial offerings for the life sciences sector.
Everest Group, a prominent global research and consulting firm, has designated Indegene as a Leader in its Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025. This assessment underscores Indegene’s extensive AI and Analytics solutions tailored for the life sciences commercial function, solidifying its role as a key transformation partner for organizations in this sector.
Indegene’s commitment to innovation is evident in its continuous efforts to integrate Generative AI (GenAI) and Agentic AI capabilities throughout its commercial solutions portfolio. This includes strategic investments in conversational AI, content summarization engines, and multi-agent orchestration frameworks, all designed to facilitate intelligent and contextualized automation.
The Everest Group report specifically lauded Indegene’s unique ability to merge its AI and Analytics expertise with profound domain knowledge. This synergy enables the company to deliver highly contextualized commercial solutions across a wide array of therapy areas, with specialized offerings for emerging fields such as specialty care, oncology, and rare diseases.
Durga Ambati, Practice Director at Everest Group, commented on the evolving landscape: ‘The increasing emphasis on patient- and HCP-centricity to deliver superior customer experiences has modernized commercialization strategies, placing data, analytics, and AI at the core of life sciences enterprises’ go-to-market efforts. As a result, they are turning to strategic partners with domain-led digital expertise and scalable technology solutions to navigate the evolving landscape.’ Ambati further added, ‘Indegene’s broad portfolio of solutions within its NEXT platform, as well as its continued investments in embedding GenAI and Agentic AI across its capabilities, are well-complemented by its diverse therapeutic knowledge and strong market-facing assets. These factors have led to Indegene earning a Leader position in Everest Group’s Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.’
The assessment by Everest Group evaluated 30 service providers based on their AI and Analytics vision, capabilities, and market impact. The rigorous evaluation criteria encompassed vision and strategy, scope of services, innovation and investments, delivery footprint, market adoption, portfolio mix, and client value delivered.
Also Read:
- FDA’s Embrace of Generative AI Prompts Call for Transparency and Validation in Pharmaceutical and Biotech Sectors
- Cognizant Unveils New AI Training Data Services to Empower Enterprise AI Development
Indegene’s unified, enterprise-wide AI approach is already yielding significant operational efficiencies and productivity gains for life sciences companies, accelerating their journey towards future readiness. This recognition follows Indegene’s strong financial performance in the first quarter, where it reported 1.8% QoQ revenue growth and highlighted strategic growth initiatives. Indegene also received recognition as a front-runner in generative AI (GenAI) life sciences market adoption in an earlier Everest Group report from February 2025, which assessed GenAI capabilities based on scale, use cases, partnerships, and client value.
